Mylan N.V. News (NASDAQ:MYL)

DateTimeSource
Headline
04/20/20171:39PMPRNUSMylan Launches Generic Trilafon Tablets
Mylan Launches Generic Trilafon Tablets PR Newswire HERTFORDSHIRE, England and PITTSBURGH, April 20, 2017 HERTFORDSHIRE, England and PITTSBURGH, April 20, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Perphenazine Tablets USP, 2 mg, 4 mg, 8 mg and 16 mg, a generic version of the... More...>>
03/31/20175:11PMPRNUSMylan Provides Update on Meridian Medical Technologies', a Pfizer Company, Expanded Voluntary Worldwide Recall of EpiPen® Au...
Mylan Provides Update on Meridian Medical Technologies', a Pfizer Company, Expanded Voluntary Worldwide Recall of EpiPen® Auto-Injector PR Newswire HERTFORDSHIRE, England and PITTSBURGH, March 31, 2017 HERTFORDSHIRE, England and PITTSBURGH, March 31, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced... More...>>
03/29/20174:30PMPRNUSMylan Completes Acquisition of Cold-EEZE® Brand
Mylan Completes Acquisition of Cold-EEZE® Brand PR Newswire HERTFORDSHIRE, England and PITTSBURGH, March 29, 2017 HERTFORDSHIRE, England and PITTSBURGH, March 29, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the successful acquisition of the global rights to the Cold-EEZE® brand cold remedy line... More...>>
03/29/20171:16PMPRNUSMylan Comments on Generic Advair Diskus® Abbreviated New Drug Application
Mylan Comments on Generic Advair Diskus® Abbreviated New Drug Application PR Newswire HERTFORDSHIRE, England and PITTSBURGH, March 29, 2017 HERTFORDSHIRE, England and PITTSBURGH, March 29, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today commented on the status of its abbreviated new drug application (ANDA... More...>>
03/28/20179:00AMPRNUSMylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer
Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer PR Newswire HERTFORDSHIRE, England and PITTSBURGH, March 28, 2017 HERTFORDSHIRE, England and PITTSBURGH, March 28, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the appointment of Daniel M. Gallagher as chief legal officer... More...>>
03/20/20171:14PMPRNUSMylan Receives Tentative Approval for "TLE400" Under PEPFAR
Mylan Receives Tentative Approval for "TLE400" Under PEPFAR - TLE400 is a fixed-combination containing Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg - PR Newswire HERTFORDSHIRE, England and PITTSBURGH, March 20, 2017 HERTFORDSHIRE, England and PITTSBURGH, March 20, 2017... More...>>
03/13/20172:21PMPRNUSMylan Launches Generic Aromasin® Tablets
Mylan Launches Generic Aromasin® Tablets PR Newswire HERTFORDSHIRE, England and PITTSBURGH, March 13, 2017 HERTFORDSHIRE, England and PITTSBURGH, March 13, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Exemestane Tablets, 25 mg, a generic version of the reference listed drug... More...>>
03/13/20178:00AMPRNUSMylan Announces Global Settlement and License Agreements with Genentech and Roche on Herceptin®
Mylan Announces Global Settlement and License Agreements with Genentech and Roche on Herceptin® PR Newswire HERTFORDSHIRE, England and PITTSBURGH, March 13, 2017 HERTFORDSHIRE, England and PITTSBURGH, March 13, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that Mylan has agreed to the terms of a... More...>>
03/10/201711:00AMPRNUSMylan to Present at Barclays Global Healthcare Conference
Mylan to Present at Barclays Global Healthcare Conference PR Newswire HERTFORDSHIRE, England and PITTSBURGH, March 10, 2017 HERTFORDSHIRE, England and PITTSBURGH, March 10, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the company will present at the Barclays Global Healthcare Conference on... More...>>
03/10/20177:30AMPRNUSMylan Launches Generic Pristiq® Tablets
Mylan Launches Generic Pristiq® Tablets PR Newswire HERTFORDSHIRE, England and PITTSBURGH, March 10, 2017 HERTFORDSHIRE, England and PITTSBURGH, March 10, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Desvenlafaxine Extended-release Tablets, 50 mg and 100 mg, a generic version... More...>>
03/01/20179:46AMDJNHot Stocks to Watch in the U.S. and Canada
Among the companies with shares expected to trade actively in Wednesday's session are Best Buy Co. (BBY), Weight Watchers International Inc. (WTW), and Lowe's Cos. (LOW). Best Buy posted a surprise decline in revenue in the final quarter of the year as it struggled to make certain products available to customers... More...>>
03/01/20177:45AMPRNUSMylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance
Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance Fourth Quarter Total Revenues Increase 31% and Full Year 2016 Total Revenues Increase 18% PR Newswire HERTFORDSHIRE, England and PITTSBURGH, March 1, 2017 HERTFORDSHIRE, England and PITTSBURGH, March 1, 2017 /PRNewswire/ -- Mylan N.V... More...>>
02/16/20178:08AMPRNUSU.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review Second Successful BLA Filing of the Partnership in the U.S. PR Newswire HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Feb. 16, 2017 HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India... More...>>
02/14/20171:59PMPRNUSMylan Applauds the Generic Pharmaceutical Association's Rebrand to the Association for Accessible Medicines
Mylan Applauds the Generic Pharmaceutical Association's Rebrand to the Association for Accessible Medicines PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Feb. 14, 2017 HERTFORDSHIRE, England and PITTSBURGH, Feb. 14, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today applauds the rebranding of the Generic Pharmaceutical... More...>>
02/03/20176:33AMPRNUSMylan to Host Investor Day on March 1, 2017 in New York City
Mylan to Host Investor Day on March 1, 2017 in New York City PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Feb. 3, 2017 HERTFORDSHIRE, England and PITTSBURGH, Feb. 3, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will host an Investor Day on March 1, 2017 in New York City. Mylan CEO Heather... More...>>
02/01/20173:02AMDJNMore Headaches for Drugmakers -- WSJ
By Peter Loftus and Preetika Rana The U.S. pharmaceutical industry has been under pressure over high and rising drug prices. Now after criticism from the White House, it's feeling the heat for where it makes its products, too. "I want you to manufacture in the United States," President Donald Trump told... More...>>
01/30/20176:51PMPRNUSMylan Wins U.S. District Court Ruling Related to Copaxone® 40 mg/mL Patents
Mylan Wins U.S. District Court Ruling Related to Copaxone® 40 mg/mL Patents PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Jan. 30, 2017 HERTFORDSHIRE, England and PITTSBURGH, Jan. 30, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the United States District Court for the District of Delaware... More...>>
01/19/20174:27PMDJNRival to EpiPen Allergy Treatment to Return to Market--Update
By Jonathan D. Rockoff The maker of an EpiPen rival said its emergency allergy treatment would return to the market on Feb. 14, adding more competition to the market for the costly products. Privately held Kaleo, the maker of the Auvi-Q injectors, said it had corrected the manufacturing problems that triggered a recall... More...>>
01/19/20173:17PMDJNRival to EpiPen Allergy Treatment to Return to Market
By Jonathan D. Rockoff The maker of an EpiPen rival said its emergency allergy treatment would return to the market on Feb. 14, adding more competition to the market for the costly products. Privately held Kaleo, the maker of the Auvi-Q injectors, said it had corrected the manufacturing problems that triggered a recall... More...>>
01/12/20175:03PMDJNCigna Drops Coverage of Mylan's EpiPen for Cheaper Generic -- Update
By Anne Steele and Joseph Walker A top U.S. health insurer has dropped its coverage of Mylan NV's brand-name EpiPen and switched to the half-priced version Mylan launched in response to public outrage over its sharp price increases on the lifesaving drug. Cigna Corp. swapped its coverage of the $600 EpiPen for Mylan's... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V:us D:20170426 09:52:39